PENTAMIDINE ISETHIONATE | N019887 | FRESENIUS KABI USA LLC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 364 | — → 1991-09 | |
| N/A | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | — → 1992-01 | |
| N/A | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 45 | — → 1991-06 | |
| N/A | Completed | Fisons | — | — | |
| Phase 3 | Completed | Glaxo Wellcome | 615 | — | |
| N/A | Completed | LyphoMed | — | — | |
| Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 400 | — → 1994-06 | |
| Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 322 | — → 1991-08 | |
| N/A | Completed | LyphoMed | — | — | |
| N/A | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | — → 1991-06 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$89.39
Highest Price
$97.28
FSS NDCs
1
Big4 NDCs
1
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 63323-0877-15PENTAMIDINE ISETHIONATE INHALER 300MG/15ML | $97.28 | FSS | Fresenius Kabi, LLC | 05/14/2030 |
| 63323-0877-15PENTAMIDINE ISETHIONATE INHALER 300MG/15ML | $89.39 | Big4 | Fresenius Kabi, LLC | 05/14/2030 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
Total Spending
$138K
Total Claims
1,802
Beneficiaries
486
ASP Price
$77.67
Spending Trend
HCPCS: J2545 — Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg
Source: CMS Medicare Part B Spending by Drug (2024). Shows physician-administered drug costs.
2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Feb 14, 2011 | SUPPL -14 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.